SCHEMBL3706142

SCHEMBL3706142

CC(C)(C)N(CCC#N)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
MAPT P10636 1/20 0.38
POLB P06746 2/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
MLYCD O95822 3/20 0.34
USP2 O75604 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
NPC1 O15118 2/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
HTT P42858 1/20 0.32
DPP4 P27487 1/20 0.31
TSHR P16473 1/20 0.30
LMNA P02545 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036652 0.80 ALDH1A1 (0.33) ALDH1A1MAPTHPGDCASP1MLYCD
SCHEMBL16781253 0.79 KDM4E (0.33) ALDH1A1MAPTHPGDHSD17B10L3MBTL1
SCHEMBL7059455 0.78 DPP4 (0.40) L3MBTL1MEN1KMT2AHTTDPP4
SCHEMBL2815049 0.77 ALDH1A1 (0.32) ALDH1A1MAPTHPGDCASP1MLYCD
Acetonitrile SCHEMBL30270573 0.76 MEN1 (0.31) L3MBTL1MEN1KMT2AHTT
SCHEMBL17183926 0.76
SCHEMBL12258511 0.74 DPP4 (0.35) ALDH1A1MAPTCASP1MLYCDMEN1
SCHEMBL332512 0.73 CA12 (0.36) ALDH1A1HPGDL3MBTL1NPC1MEN1
SCHEMBL319857 0.73 MEN1 (0.35) ALDH1A1MAPTMLYCDL3MBTL1NPC1
SCHEMBL1878409 0.72 POLB (0.42) ALDH1A1MAPTPOLBHPGDCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160223559-A1 TETRAZINE-CONTAINING COMPOUNDS AND SYNTHETIC METHODS THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-08-04 US disclosed
US-20140081025-A1 HETEROAROMATIC RING DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-03-20 US disclosed
EP-2708537-A1 HETEROAROMATIC RING DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2014-03-19 EP disclosed
WO-2010100144-A1 FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE MERCK SERONO S.A. (CH) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140081025-A1 HETEROAROMATIC RING DERIVATIVE HCRTR2, HCRTR1, HTT ALDH1A1 1060/4885MAPT 413/4885POLB 3638/4885
US-20160223559-A1 TETRAZINE-CONTAINING COMPOUNDS AND SYNTHETIC METHODS THEREOF HCK, TTK, TLK1 ALDH1A1 3233/4885MAPT 1070/4885POLB 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.